Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer.
Sazan RasulMarkus HartenbachTim WollenweberElisabeth Kretschmer-ChottBernhard GrubmüllerGero KramerShahrokh ShariatWolfgang WadsakMarkus MitterhauserVerena PichlerChrysoula VrakaMarcus HackerAlexander R HaugPublished in: European journal of nuclear medicine and molecular imaging (2020)
Basal Hb level is an independent predictor for therapy response and survival in patients receiving PSMA-RLT every 4 weeks. Both baseline PSA ≤ 650 μg/L and normal Hb levels were associated with longer survival.